{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:22Z","timestamp":1790352202010,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This retrospective cohort study evaluated the therapeutic efficacy and safety profile of telitacicept, a novel dual B-cell-activating factor (BAFF)\/a proliferation-inducing ligand (April) inhibitor, in managing systemic lupus erythematosus (SLE) patients with lupus nephritis (LN) and nephrotic syndrome (NS), with particular focus on renal and hematological parameters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>12 SLE patients with biopsy-confirmed LN and NS who received weekly subcutaneous telitacicept (80\/160\u00a0mg) combined with standard therapies for \u226512\u00a0months were analyzed. Primary endpoints include changes in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores, 24-h urinary protein excretion (24hUpr), complement levels (Complement Component 3\/Complement Component 4), anti-double-stranded DNA antibodies (anti-dsDNA) titers, immunoglobulin profiles, serum creatinine, and hemoglobin (HGB) at baseline, 3-month, and 12-month intervals. Statistical analysis was performed using SPSS 26.0 and R 4.1.2. The significance level was assessed using a one-sample t-test of the log ratios, with the null hypothesis assuming no effect.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Significant improvements were observed in the cohort (91.7% female, median age 30): SLEDAI: Median reduction from 13 to 4 (p = 0.0029), 24hUpr: 4.0\u00a0g\/24\u00a0h \u2192 0.83\u00a0g\/24\u00a0h (p &amp;lt; 0.001), anti-dsDNA: 120\u00a0IU\/mL \u2192 13\u00a0IU\/mL (p = 0.003), Complement restoration: C3 0.56\u21920.84\u00a0g\/L; C4 0.1\u21920.22\u00a0g\/L (both p &amp;lt; 0.001), HGB improvement: 110\u2192120\u00a0g\/L (p = 0.0144). Compared to 80\u00a0mg dose subgroup, the 160\u00a0mg dose subgroup (83.3%) showed superior outcomes with no severe adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Telitacicept demonstrates robust clinical efficacy in LN-NS management through dual B-cell regulation and complement restoration mechanisms. These practical findings support its potential as a targeted therapy for renal and hematological manifestations of SLE, requiring further validation through randomized controlled trials.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1613790","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T06:03:15Z","timestamp":1752818595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of telitacicept in systemic lupus erythematosus with lupus nephritis and nephrotic syndrome: a 12-month retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Min-Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Sen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Song","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102873","DOI":"10.1016\/j.jaut.2022.102873","article-title":"B cell-targeted therapies in systemic lupus erythematosus","volume":"132","author":"Arbitman","year":"2022","journal-title":"J. Autoimmun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/TCRM.S252592","article-title":"Emerging B-Cell therapies in systemic lupus erythematosus","volume":"17","author":"Bag-Ozbek","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"B3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40744-020-00212-9","article-title":"Systemic lupus erythematosus (SLE) therapy: the old and the new","volume":"7","author":"Basta","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1169084","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s41927-023-00358-3","article-title":"Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE)","volume":"7","author":"Chan","year":"2023","journal-title":"BMC Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/BOR.0000000000000777","article-title":"Cellular aspects of the pathogenesis of lupus nephritis","volume":"33","author":"Chang","year":"2021","journal-title":"Curr. Opin. Rheumatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/rheumatology\/kead674","article-title":"The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis","volume":"64","author":"Chen","year":"2023","journal-title":"Rheumatol. Oxf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1007\/s10067-024-06992-7","article-title":"Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement","volume":"43","author":"Cheng","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J. Autoimmun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/biomedicines12030569","article-title":"Nephrotic syndrome: from pathophysiology to novel therapeutic approaches","volume":"12","author":"Fr\u0103\u021bil\u0103","year":"2024","journal-title":"Biomedicines"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"v39","DOI":"10.1093\/rheumatology\/keaa381","article-title":"Lupus nephritis: clinical presentations and outcomes in the 21st century","volume":"59","author":"Gasparotto","year":"2020","journal-title":"Rheumatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1270011","DOI":"10.3389\/fimmu.2023.1270011","article-title":"Case report: telitacicept in severe myasthenia gravis: a case study with multiple autoantibodies","volume":"14","author":"Guo","year":"2023","journal-title":"Front. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10067-024-07266-y","article-title":"Effectiveness and safety of belimumab and telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study","volume":"44","author":"Jin","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1159\/000527213","article-title":"Aberrant B-Cell activation in systemic lupus erythematosus","volume":"8","author":"Kang","year":"2022","journal-title":"Kidney Dis. (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","article-title":"Treat-to-target in systemic lupus erythematosus: advancing towards its implementation","volume":"18","author":"Parra S\u00e1nchez","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2072143","DOI":"10.1080\/21645515.2022.2072143","article-title":"Belimumab for systemic lupus erythematosus-Focus on lupus nephritis","volume":"18","author":"Pl\u00fc\u00df","year":"2022","journal-title":"Hum. Vaccin Immunother."},{"key":"B19","volume-title":"R: a language and environment for statistical computing","year":"2021"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6236","DOI":"10.1038\/s41598-020-63390-0","article-title":"Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients","volume":"10","author":"Salazar-Camarena","year":"2020","journal-title":"Sci. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.autrev.2017.01.010","article-title":"Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review","volume":"16","author":"Sciascia","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"999704","DOI":"10.3389\/fimmu.2022.999704","article-title":"Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials","volume":"13","author":"Steiger","year":"2022","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann. rheumatic Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/eji.201646630","article-title":"TACI-Dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus","volume":"47","author":"Tran","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine and Growth Factor Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4 475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann. rheumatic Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s40001-023-01320-2","article-title":"Role of telitacicept in the treatment of IgA nephropathy","volume":"28","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1177\/09612033241241576","article-title":"The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: a retrospective cohort study","volume":"33","author":"Wu","year":"2024","journal-title":"Lupus"},{"key":"B30","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2023","journal-title":"Rheumatology"},{"key":"B31","first-page":"51","article-title":"Research progress of telitacicept in IgA nephrophy and lupus nephritis","volume":"32","author":"Yang","year":"2022","journal-title":"China J. Mod. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"6231","DOI":"10.3390\/ijms20246231","article-title":"B cell abnormalities in systemic lupus erythematosus and lupus nephritis\u2014role in pathogenesis and effect of immunosuppressive treatments","volume":"20","author":"Yap","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3390\/jpm13040691","article-title":"Early and late response and glucocorticoid-sparing effect of belimumab in patients with systemic lupus erythematosus with joint and skin manifestations: results from the belimumab in real life setting study-joint and skin (BeRLiSS-JS)","volume":"13","author":"Zen","year":"2023","journal-title":"J. Pers. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e954","DOI":"10.1002\/iid3.954","article-title":"Efficacy and safety of belimumab therapy for patients with lupus nephritis: a meta-analysis and a propensity score-matched case-control study","volume":"11","author":"Zhang","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"997","DOI":"10.55563\/clinexprheumatol\/4uc7e8","article-title":"Systemic lupus erythematosus: one year in review 2023","volume":"41","author":"Zucchi","year":"2023","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1613790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T06:03:16Z","timestamp":1752818596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1613790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":35,"alternative-id":["10.3389\/fphar.2025.1613790"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1613790","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"article-number":"1613790"}}